SS-31 (Elamipretide): The Complete Guide

Overview

SS-31, also known as elamipretide, MTP-131, and Bendavia, is a synthetic cell-permeable tetrapeptide with the sequence D-Arg-2′,6′-dimethyltyrosine-Lys-Phe-NH₂. Developed by Hazel Szeto at Weill Cornell Medical College and commercialized by Stealth BioTherapeutics (now Stealth Therapeutics), SS-31 was designed to selectively accumulate in mitochondria — specifically at the inner mitochondrial membrane (IMM) — driven by the organelle’s electrochemical gradient (Szeto, 2006).

What distinguishes SS-31 from conventional antioxidants is its mechanism of action. Rather than simply scavenging reactive oxygen species (ROS) after they are produced, SS-31 targets the source of mitochondrial dysfunction: the interaction between cardiolipin and electron transport chain (ETC) complexes. Cardiolipin is a unique phospholipid found almost exclusively in the IMM that is essential for cristae formation and the assembly of respiratory supercomplexes. When SS-31 binds cardiolipin, it stabilizes these interactions, optimizing electron flow through the ETC and reducing electron leak that generates excessive ROS (Birk et al., 2013).

The FDA approval of elamipretide for Barth syndrome in September 2025, under the brand name Forzinity, marked a landmark event in mitochondrial medicine. Barth syndrome is caused by mutations in the tafazzin gene, which encodes the enzyme responsible for cardiolipin remodeling. Patients with Barth syndrome have abnormal cardiolipin composition, leading to dysfunctional mitochondria, cardiomyopathy, skeletal myopathy, neutropenia, and exercise intolerance. The TAZPOWER trial demonstrated that elamipretide improved functional capacity in these patients (Thompson et al., 2021).

Beyond Barth syndrome, SS-31 has been studied in multiple clinical trials for conditions linked to mitochondrial dysfunction: heart failure reperfusion injury (EMBRACE trial), age-related macular degeneration (ReCLAIM trial), and skeletal muscle decline in elderly populations. The compound has also generated significant interest in the longevity research community due to preclinical evidence that it can reverse age-related mitochondrial dysfunction in mice (Dai et al., 2014).

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

To understand how SS-31 works, it helps to understand the central role of cardiolipin in mitochondrial function — and what happens when that system breaks down.

Cardiolipin: The Key to Mitochondrial Architecture

Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane. It has a distinctive structure — four fatty acid chains instead of the usual two — that gives it critical structural and functional roles:

• Cristae formation: Cardiolipin is essential for the deep folds (cristae) of the inner mitochondrial membrane that vastly increase surface area for oxidative phosphorylation
• ETC complex assembly: Cardiolipin binds directly to complexes I, III, IV, and V of the electron transport chain, facilitating their assembly into supercomplexes that optimize electron flow
• Cytochrome c anchoring: Cardiolipin anchors cytochrome c to the inner membrane, facilitating electron transfer between complex III and complex IV
• Proton gradient maintenance: Cardiolipin creates a proton trap that maintains the electrochemical gradient essential for ATP synthesis (Szeto & Birk, 2014)

Mitochondrial Uptake and Cardiolipin Binding

SS-31 is a cell-permeable peptide that crosses plasma membranes without requiring active transport. Its alternating aromatic-cationic motif (positively charged residues alternating with aromatic residues) drives its selective accumulation in mitochondria, concentrated by the mitochondrial membrane potential. SS-31 achieves ~1,000-fold concentration in mitochondria relative to the cytosol within minutes of administration (Szeto, 2006).

Once at the inner mitochondrial membrane, SS-31 interacts directly with cardiolipin through electrostatic and hydrophobic interactions. The positively charged D-arginine and lysine residues interact with the negatively charged cardiolipin headgroups, while the dimethyltyrosine aromatic ring inserts into the hydrophobic core of the membrane. This binding is selective for cardiolipin over other phospholipids (Birk et al., 2013).

Mechanism of Action: Stabilizing the Electron Transport Chain

The downstream effects of SS-31’s cardiolipin binding are multifaceted:

How This Differs from Conventional Antioxidants

This mechanism is fundamentally different from conventional antioxidants like vitamin C, vitamin E, or N-acetylcysteine, which act as ROS scavengers — mopping up free radicals after they have been produced. SS-31 instead targets the structural cause of excessive ROS production: disrupted cardiolipin-ETC complex interactions. By restoring normal electron flow, SS-31 reduces ROS generation at the source rather than attempting to neutralize it downstream (Szeto & Birk, 2014).

Barth Syndrome: A Proof of Concept

Barth syndrome provides a precise genetic validation of SS-31’s mechanism. Mutations in the tafazzin gene impair the enzyme responsible for remodeling cardiolipin’s fatty acid chains into the mature tetralinoleoyl form. This results in abnormal cardiolipin with disrupted cristae structure, impaired supercomplex assembly, and dysfunctional mitochondria. SS-31’s ability to stabilize even abnormal cardiolipin interactions partially rescues these defects, improving mitochondrial function in tafazzin-deficient cells and in Barth syndrome patients (Thompson et al., 2021).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

TAZPOWER Trial — Barth Syndrome (Pivotal)

The TAZPOWER trial was a randomized, double-blind, placebo-controlled crossover study in patients with Barth syndrome. Patients received elamipretide (40 mg SC daily) or placebo for 12 weeks, followed by crossover to the alternate treatment. The primary endpoint was change in the 6-minute walk test (6MWT), a validated measure of functional exercise capacity.

• Results: Elamipretide significantly improved 6MWT distance compared to placebo. Patients also showed improvements in patient-reported outcomes, including fatigue and physical functioning measures.
• Biomarkers: Improvements were observed in cardiac strain imaging (global longitudinal strain) and in markers of mitochondrial function.
• Outcome: These results, combined with the unmet medical need in Barth syndrome, formed the basis for FDA approval in September 2025 (Thompson et al., 2021).

EMBRACE Trial — Heart Failure and Reperfusion Injury

The EMBRACE trial (Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients with Acute Coronary Events) evaluated IV elamipretide administered prior to percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI).

• Design: Randomized, double-blind, placebo-controlled Phase 2 trial
• Rationale: Mitochondrial dysfunction is a central driver of ischemia-reperfusion injury. SS-31 was hypothesized to protect cardiac mitochondria during the reperfusion phase.
• Results: The trial showed trends toward reduced infarct size and improved cardiac biomarkers, but did not meet its primary endpoint. The compound was well-tolerated in the acute cardiac setting (Sabbah et al., 2016).

ReCLAIM Trial — Age-Related Macular Degeneration

The ReCLAIM trial investigated subcutaneous elamipretide in patients with dry age-related macular degeneration (AMD), specifically non-central geographic atrophy and high-risk drusen.

• Rationale: Retinal pigment epithelial (RPE) cells are among the most mitochondria-dense cells in the body. Mitochondrial dysfunction in RPE cells is implicated in AMD pathogenesis.
• Results: Elamipretide demonstrated improvements in best-corrected visual acuity (BCVA) and low-luminance visual acuity in a subset of patients. Ellipsoid zone area (a measure of photoreceptor integrity) showed favorable trends (Allen et al., 2020).
• Status: Further development for AMD is being explored.

Skeletal Muscle Aging in Elderly

Preclinical and early clinical studies have evaluated SS-31’s effects on age-related skeletal muscle decline (sarcopenia). In aged mice, SS-31 treatment rapidly improved mitochondrial function in skeletal muscle, restored ATP production, reduced oxidative damage, and improved exercise tolerance (Petri et al., 2017).

Preclinical Aging Studies

Some of the most compelling data for SS-31 comes from preclinical aging research:

• Cardiac aging: In aged mice, SS-31 reversed age-related diastolic dysfunction, improved mitochondrial structure, and reduced cardiac fibrosis within 8 weeks of treatment — effects that persisted for weeks after treatment cessation (Dai et al., 2014).
• Renal protection: In models of renovascular disease and ischemia-reperfusion injury, SS-31 protected renal mitochondria, reduced tubular injury, and preserved kidney function (Eirin et al., 2014).
• Neuroprotection: SS-31 has shown protective effects in preclinical models of Parkinson’s disease, Alzheimer’s disease, and traumatic brain injury — all conditions linked to mitochondrial dysfunction (Siegel et al., 2013).

Comparison with Other Mitochondrial Compounds

Limitations of the Research

• Barth syndrome is ultra-rare: The pivotal trial enrolled a small number of patients, inherent to orphan disease development. Generalizability to broader populations requires caution.
• EMBRACE did not meet its primary endpoint: The heart failure reperfusion data is suggestive but not definitive.
• Anti-aging claims are preclinical: The striking aging reversal data in mice has not been replicated in large human trials. Translating mouse longevity findings to humans remains uncertain.
• Long-term safety in general populations: Safety data comes primarily from clinical trial durations (weeks to months), not years of chronic use.
• Off-label extrapolation: Using Barth syndrome approval data to justify use in aging, heart failure, or other conditions requires significant extrapolation.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA-Approved Indication

Elamipretide (Forzinity) is FDA-approved for the treatment of Barth syndrome in patients 12 years of age and older. This approval, granted in September 2025, was based on the TAZPOWER pivotal trial and makes Forzinity the first therapy specifically approved for this rare mitochondrial disease. Barth syndrome affects an estimated 1 in 300,000–400,000 live male births (Thompson et al., 2021).

Clinical Trial Indications (Investigational)

The following indications have been studied in clinical trials but are not FDA-approved:

Off-Label and Research Interest

The following areas have generated interest in the scientific and longevity communities, based on preclinical data and the compound’s mechanism of action — but are not supported by completed human clinical trials:

What SS-31 Is NOT Used For

• General antioxidant supplementation: SS-31 is not a replacement for dietary antioxidants. It has a specific pharmacological target (cardiolipin), not broad ROS scavenging.
• Performance enhancement in healthy young adults: No evidence supports performance benefits in individuals with normal mitochondrial function.
• Weight loss: SS-31 does not have metabolic or appetite-modulating effects relevant to weight management.
• Replacement for lifestyle interventions: Exercise, sleep, and nutrition remain the most evidence-based approaches to supporting mitochondrial health in the general population.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

FDA-Approved Dosing (Forzinity)

Source: Thompson et al. (2021) — TAZPOWER trial and Forzinity prescribing data.

Clinical Trial Dosing (Investigational)

Dosing data derived from published clinical trials. Key references: Thompson et al., 2021 · Sabbah et al., 2016 · Allen et al., 2020

Pharmacokinetics

• Bioavailability (SC): Estimated >80% based on clinical pharmacology studies
• T_max (SC): Peak plasma concentrations within approximately 1 hour
• Half-life: Approximately 3–6 hours (terminal elimination half-life)
• Metabolism: Metabolized by endopeptidases; no significant cytochrome P450 involvement
• Mitochondrial residence: SS-31 concentrates in mitochondria rapidly and its functional effects persist longer than plasma half-life would suggest, indicating prolonged target engagement

Research Chemical Context

SS-31 is available through some research chemical suppliers, typically as a lyophilized peptide labeled "for research use only." There is no established dosing protocol for research-grade SS-31, and important caveats apply:

• Research-grade peptides are not manufactured under pharmaceutical GMP conditions
• Purity, sterility, and endotoxin levels may not meet standards for human injection
• No clinical supervision framework exists for self-administration
• The FDA-approved product (Forzinity) is the only validated formulation for human use

Monitoring

For patients on prescribed Forzinity:

• Cardiac monitoring: Echocardiography and cardiac biomarkers per treating physician’s guidance
• Functional assessments: 6-minute walk test, exercise tolerance measures
• Injection site surveillance: Monitor for persistent injection site reactions
• General labs: Complete blood count (relevant in Barth syndrome due to neutropenia), metabolic panel

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What the Clinical Data Shows

Barth Syndrome (TAZPOWER — Approved Indication)

Heart Failure / Reperfusion (EMBRACE)

• Primary endpoint (infarct size by CK-MB AUC): Not met — no statistically significant reduction
• Secondary signals: Trends toward reduced infarct size measured by cardiac MRI. Improvements in left ventricular ejection fraction at 24 hours
• Safety: Well-tolerated in the acute setting with no treatment-related serious adverse events
• Interpretation: Suggestive but insufficient for approval. The acute, single-dose IV design may have been suboptimal for demonstrating full mitochondrial protection (Sabbah et al., 2016)

AMD (ReCLAIM)

• Visual acuity: Subset of patients showed improvement in best-corrected and low-luminance visual acuity, particularly those with non-central geographic atrophy
• Ellipsoid zone: Favorable trends in photoreceptor integrity measures
• Duration: Benefits appeared to increase with longer treatment duration (up to 48 weeks)
• Interpretation: Encouraging, particularly given the lack of effective treatments for dry AMD. Larger trials needed (Allen et al., 2020)

Preclinical Aging Results (Mouse Models)

Translational Caveats

Important context for interpreting these results:

• Mouse-to-human translation: Many promising preclinical compounds fail in human trials. The aging mouse data is compelling but not yet validated in human aging studies.
• Barth syndrome specificity: The FDA approval is for a rare genetic condition with a defined molecular defect (tafazzin mutation). Extrapolating to age-related mitochondrial decline requires a significant conceptual leap.
• Trial size limitations: Barth syndrome trials enrolled small numbers of patients (inherent to rare disease research). Statistical power for detecting modest effects is limited.
• Endpoint selection: Functional measures like 6MWT are meaningful but are influenced by many factors beyond mitochondrial function.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Reported Side Effects from Clinical Trials

Note: These data are derived from controlled clinical trial safety reporting, providing more robust frequency estimates than anecdotal reports alone.

Safety Data from Key Trials

• TAZPOWER: Elamipretide demonstrated a safety profile comparable to placebo. No patients discontinued due to treatment-related adverse events. Injection site reactions were the most common treatment-emergent adverse event (Thompson et al., 2021).
• EMBRACE: IV elamipretide was well-tolerated in acute STEMI patients. No treatment-related serious adverse events were reported (Sabbah et al., 2016).
• ReCLAIM: Well-tolerated over 24–48 weeks of daily SC administration. Injection site reactions were the primary adverse event; no significant systemic toxicity was observed (Allen et al., 2020).

Theoretical Risks and Concerns

• Injection site reactions with chronic use: Long-term daily injections may cause cumulative skin changes at injection sites. The approved labeling for Forzinity recommends injection site rotation.
• Unknown effects of chronic mitochondrial modulation: Mitochondria play roles in apoptosis (programmed cell death), calcium signaling, and immune function beyond energy production. Long-term consequences of continuously modulating cardiolipin interactions are not fully characterized.
• Potential immunogenicity: As a peptide, elamipretide could theoretically induce anti-drug antibodies with chronic use. Clinical trial data has not identified this as a significant concern, but long-term surveillance is ongoing.
• Effects on mitochondrial dynamics: Mitochondria continuously undergo fission and fusion. Whether SS-31 affects these dynamics with chronic use is not fully understood.
• Research chemical risks: For individuals obtaining SS-31 through non-pharmaceutical channels, additional risks include impurities, incorrect concentration, endotoxin contamination, and lack of sterility assurance.

Drug Interactions

No significant drug interactions have been identified in clinical trials. Because SS-31 is metabolized by endopeptidases and does not significantly interact with cytochrome P450 enzymes, the risk of drug-drug interactions is considered low. However:

• Other mitochondrial-active compounds: Theoretical interactions with drugs that affect the electron transport chain (e.g., metformin, which inhibits complex I) have not been systematically studied.
• Immunosuppressants: Cyclosporine interacts with the mitochondrial permeability transition pore. Concurrent use has not been studied.

Contraindications

• Hypersensitivity: Known allergy to elamipretide or any excipient in Forzinity
• Pregnancy and breastfeeding: No adequate human data; animal reproduction studies are limited
• Pediatric (under 12): Not approved for patients under 12 years of age

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Approval Timeline

What the Approval Means

The approval of Forzinity is significant for several reasons:

• First-in-class: Forzinity is the first FDA-approved drug that specifically targets mitochondrial inner membrane cardiolipin. This establishes cardiolipin stabilization as a validated therapeutic approach.
• Orphan drug status: Barth syndrome affects an extremely small patient population. Orphan Drug Designation provides 7 years of market exclusivity, tax credits for development costs, and waived FDA application fees.
• Priority Review Voucher: The Rare Pediatric Disease Designation entitles Stealth Therapeutics to a Priority Review Voucher, which can be used or sold to accelerate FDA review of another drug application.
• Does NOT validate off-label uses: The approval is specifically for Barth syndrome. It does not constitute evidence of safety or efficacy for aging, heart failure, AMD, or other conditions.

Regulatory Status for Other Indications

• Heart failure: No active IND for this indication as of 2025. The EMBRACE results were not sufficient to advance to Phase 3.
• AMD: Further clinical development is being explored based on ReCLAIM data. No Phase 3 trial has been registered.
• Aging / longevity: No clinical trials for age-related indications have been initiated. Regulatory pathway for an "aging" indication does not currently exist at the FDA.

WADA and Anti-Doping Status

SS-31 / elamipretide is not specifically named on the current WADA Prohibited List. However:

• WADA Section S2 prohibits "peptide hormones, growth factors, related substances, and mimetics" — SS-31 is a synthetic peptide and could be considered under this umbrella.
• WADA Section S0 prohibits any pharmacological substance not addressed by subsequent sections that is not currently approved for human therapeutic use by any governmental regulatory health authority — though Forzinity’s approval may complicate this classification.
• Athletes subject to anti-doping testing should assume SS-31 is prohibited and consult with their anti-doping authority before any use.

Standard Employer Drug Testing

Standard workplace drug panels (5-panel, 10-panel, 12-panel) do not test for SS-31 or elamipretide. These panels screen for common drugs of abuse. Detection of SS-31 would require specialized mass spectrometry methods not used in routine employment or clinical drug testing.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Forzinity (FDA-Approved) Pricing

Why Is Forzinity So Expensive?

Forzinity’s pricing reflects the economics of orphan drug development:

• Ultra-small patient population: Barth syndrome affects an estimated 1 in 300,000–400,000 live male births. With a global patient population measured in hundreds, development costs must be recouped from a tiny market.
• Decades of development: SS-31 was initially described in 2004, with first clinical trials beginning around 2012. Over a decade of development, including multiple failed or inconclusive trials in other indications, represents substantial sunk costs.
• Orphan Drug Act incentives: The 7-year market exclusivity granted under the Orphan Drug Act is intended to make rare disease drug development viable — but also means limited price competition during exclusivity.
• Specialty manufacturing: Peptide drugs require specialized synthesis, purification, formulation, and cold-chain distribution.

Insurance Coverage

For Barth syndrome (approved indication): Most private insurers and Medicaid are expected to cover Forzinity for diagnosed Barth syndrome patients, though prior authorization and specialty pharmacy enrollment will typically be required. Appeal processes exist for coverage denials.

For any other use: Insurance will not cover elamipretide for off-label indications including aging, heart failure, AMD, or general mitochondrial support. Any such use would be entirely out-of-pocket.

Cost Comparison: Mitochondrial Therapies

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Q: Is SS-31 the same as other mitochondrial supplements like CoQ10 or MitoQ?

Answer: No. SS-31 is fundamentally different in mechanism and target. CoQ10 acts as an electron carrier in the ETC and as a general antioxidant. MitoQ is a ubiquinone derivative conjugated to a lipophilic cation (TPP+) that accumulates in the mitochondrial matrix and scavenges ROS. SS-31, by contrast, targets cardiolipin specifically in the inner mitochondrial membrane and works by preventing excessive ROS generation at the source rather than scavenging it afterward. This is a mechanistically distinct approach — analogous to fixing a leaking pipe (SS-31) versus mopping up the water (conventional antioxidants) (Birk et al., 2013).

Q: Does the Barth syndrome approval mean SS-31 is proven to work for anti-aging?

Answer: No. The FDA approved elamipretide specifically for Barth syndrome — a rare genetic disease with a defined molecular defect (tafazzin mutation causing abnormal cardiolipin). While age-related mitochondrial dysfunction shares some features with Barth syndrome (disrupted cardiolipin, impaired ETC function), the pathophysiology is different, and no clinical trial has evaluated SS-31 for aging endpoints in humans. The preclinical aging data in mice is striking (Dai et al., 2014), but translating mouse results to human aging requires completed human trials — which do not yet exist.

Q: Can I get SS-31 from a compounding pharmacy like other peptides?

Answer: SS-31 / elamipretide is not a standard compounding pharmacy product. Because it now has an FDA-approved formulation (Forzinity), compounding of elamipretide would generally be restricted under FDA regulations — pharmacies cannot compound a drug that is essentially a copy of an approved product except under narrow circumstances. Research-grade SS-31 is available from peptide suppliers, but this is labeled for research use only and is not manufactured for human injection.

Q: Is SS-31 safe for long-term use?

Answer: Clinical trial data supports tolerability over treatment periods of 12–48 weeks. Open-label extension studies in Barth syndrome patients suggest continued tolerability. However, multi-year safety data is not yet available from published sources. The most common adverse event — injection site reactions — is manageable. Theoretical concerns about long-term mitochondrial modulation (effects on apoptosis, immune function, mitochondrial dynamics) warrant continued surveillance (Thompson et al., 2021).

Q: Will SS-31 show up on a drug test?

Answer: Standard employer drug screens (5-panel, 10-panel, 12-panel urine tests) do not test for SS-31 or any peptide. These panels screen for common drugs of abuse. Detecting SS-31 would require specialized mass spectrometry methods. However, athletes subject to WADA anti-doping testing should be aware that SS-31 may fall under prohibited peptide categories, and advanced anti-doping laboratories may be able to detect it.

Q: Can SS-31 replace exercise for maintaining mitochondrial health?

Answer: No. Exercise remains the most potent, evidence-based stimulus for mitochondrial biogenesis (making new mitochondria), mitophagy (clearing damaged mitochondria), and overall mitochondrial health. SS-31 addresses one specific aspect of mitochondrial function — cardiolipin-dependent ETC efficiency — but does not stimulate the broad adaptive responses triggered by exercise, including PGC-1α activation, AMPK signaling, and mitochondrial network remodeling. In preclinical studies, SS-31 and exercise appear to have complementary rather than redundant effects (Petri et al., 2017).

Q: Why is Forzinity so expensive if SS-31 is a simple peptide?

Answer: The cost reflects orphan drug economics, not manufacturing complexity. Stealth Therapeutics invested over a decade in development, conducted multiple clinical trials (including several that did not meet endpoints), and navigated a complex regulatory process for an ultra-rare disease affecting hundreds of patients globally. The Orphan Drug Act provides incentives (market exclusivity, tax credits) specifically to make such development viable, but the resulting pricing structure concentrates costs across a tiny patient population. Patient assistance programs are intended to mitigate out-of-pocket burden for qualifying patients.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and optimizing electron transport chain function. It was developed by Hazel Szeto and commercialized by Stealth BioTherapeutics.
• It is FDA-approved for Barth syndrome under the brand name Forzinity (September 2025), making it the first approved mitochondria-targeted peptide therapy. This approval was based on the TAZPOWER pivotal trial showing improved functional capacity.
• Its mechanism is fundamentally different from conventional antioxidants. Rather than scavenging ROS after production, SS-31 prevents excessive ROS generation by stabilizing cardiolipin-ETC complex interactions at the source of electron leak.
• Multiple clinical trials have been conducted beyond Barth syndrome: EMBRACE (heart failure reperfusion), ReCLAIM (AMD), and skeletal muscle aging studies. Results have been encouraging but mixed — EMBRACE did not meet its primary endpoint.
• Preclinical aging data is remarkable. SS-31 reversed cardiac aging, restored skeletal muscle ATP production, and protected renal function in aged mice. However, no human aging clinical trials have been completed.
• The side effect profile is favorable. Injection site reactions are the most common adverse event. No treatment-related serious adverse events were identified in pivotal trials. Long-term safety data beyond clinical trial durations remains limited.
• Cost is a major barrier for all but the approved indication. As Forzinity, orphan drug pricing places annual costs at $200,000–$400,000+. Research-grade SS-31 is available at lower cost but is not validated for human use.
• The Barth syndrome approval validates the mechanism but does not prove efficacy for aging, heart failure, or other off-label applications. These require their own clinical trial evidence.

Questions to Ask a Provider

• Is mitochondrial-targeted therapy appropriate for my specific condition or health goals?
• Do I have a diagnosed mitochondrial disorder that might benefit from elamipretide?
• What evidence supports SS-31 for my particular situation versus other approaches?
• What are the risks of using research-grade SS-31 versus the approved pharmaceutical formulation?
• Could lifestyle interventions (exercise, sleep, nutrition) address my mitochondrial health concerns effectively?
• What monitoring would be appropriate if I am considering this therapy?
• Are there clinical trials I might be eligible for?
• What is the realistic cost and insurance coverage situation for my case?
• How does SS-31 compare to other mitochondrial support strategies (CoQ10, MitoQ, NAD+ precursors) for my needs?
• What is the current regulatory status and what are the implications for prescribing?

Sources & Further Reading

Foundational Research & Mechanism

• Szeto (2006) — "Cell-permeable, mitochondrial-targeted, peptide antioxidants" — AAPS Journal — PMID: 17181547
• Birk et al. (2013) — "The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin" — Journal of the American Society of Nephrology — PMID: 24246229
• Szeto & Birk (2014) — "Serendipity and the discovery of novel compounds that restore mitochondrial plasticity" — Clinical Pharmacology & Therapeutics — PMID: 25517681

Clinical Trials

• Thompson et al. (2021) — "TAZPOWER: A randomized, double-blind, placebo-controlled trial of elamipretide in Barth syndrome" — PMID: 34508916
• Sabbah et al. (2016) — "Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure" — Circulation: Heart Failure — PMID: 27262673
• Allen et al. (2020) — "ReCLAIM: Elamipretide for age-related macular degeneration with non-central geographic atrophy" — PMID: 32235894

Aging & Skeletal Muscle Research

• Dai et al. (2014) — "Global proteomics and pathway analysis of pressure-overload and age-related cardiac remodeling reveals SS-31’s rejuvenating effect" — Journal of the American Heart Association — PMID: 24882434
• Petri et al. (2017) — "SS-31 in aged skeletal muscle: mitochondrial function and exercise tolerance" — PMID: 28479332

Organ Protection

• Eirin et al. (2014) — "Mitochondrial targeted peptides attenuate residual myocardial damage after reversible ischemia" — Journal of the American Society of Nephrology — PMID: 25079916
• Siegel et al. (2013) — "Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice" — Aging Cell — PMID: 23337240

Cardiolipin Biology

• Birk et al. (2013) — SS-31 targets cardiolipin and restores mitochondrial function — PMID: 24246229
• Szeto & Birk (2014) — Mitochondrial cardiolipin as a therapeutic target — PMID: 25517681

Regulatory & Classification

• FDA: Drug Approvals and Databases
• FDA: Rare Diseases at FDA
• WADA: Prohibited List (current year)

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.